Login to Your Account



Deals And M&A NEWS

Takeda Pharmaceutical Co. Ltd. and Nanotherapeutics Inc. have struck an agreement providing Takeda with expanded commercialization and technology rights to Nanotherapeutics' Vero cell technology, a manufacturing platform that's key to Takeda's flu vaccines and its aspirations to further develop its global vaccines business in other markets.

An exclusive new tie-up between Janus Biotherapeutics Inc. and Roche AG will advance what could become the first oral TLR inhibitor to enter the clinic with the potential to address autoimmune diseases.

Roche AG wove a deal worth up to $425 million for Geneweave Biosciences Inc., a private U.S. firm with technology aimed to fight drug-resistant bacteria.

More Deals And M&A Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: